2020-2027 Analysis and Review Betahistine Market

Betahistine Market

Betahistine Market By Treatment (Ménière’s Disease, Benign Paroxysmal Positional Vertigo and PWS-linked Obesity), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027

02-04-2020 REP-HC-5059 40 Tables 119 pages Format

The betahistine market was valued at USD433.3Mn by 2019. According to the latest research findings presented by the Hearing Health Foundation approximately 45,000 to 60,000 cases of Ménière’s Disease are diagnosed each year. Additionally, the orphan drug status awarded to betahistine drug for the treatment of PWS- linked obesity will further accentuate the market growth during the forecast period.

 Betahistine Market

Betahistine stimulates the H1 receptors of the inner ears and causes vasodilation to increase the permeability of the blood vessels which causes a reduction in the endolymphatic pressure. It is also helpful in reducing the asymmetrical functioning of the vestibular organs and enhances the blood flow in the vestibulocochlear region. Betahistine is a potent H3 receptor antagonist that increases the serotonin level in the brainstem region in order to prevent the activity of vestibular nuclei to treat vertigo by maintaining balance.

The major segments related to the betahistine market are:

By Treatment (2017–2027; US$ Mn)

Ménière’s Disease

Benign Paroxysmal Positional Vertigo

PWS-linked Obesity

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment(2017–2027; US$ Mn)

North America

United States
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

  • The intention of the study is to give a comprehensive outlook of the global betahistine market
  • The overall segmentation of the betahistine market, by treatment, distribution channel, and geography is minutely studied. Meniere’s disease and hospital pharmacy are dominating the treatment and distribution channel segments respectively
  • The constant rise of Meniere’s disease in the geriatric population worldwide drives the betahistine market
  • Orphan drug status awarded to betahistine for the treatment of PWS-linked obesity will further accentuate the betahistine market growth in the near future

Report gist?

  • The study of the global betahistine market includes qualitative analysis of factors such as drivers, restraints, and opportunities
  • The report covers qualitative and quantitative analysis of the overall market segmented on the basis of treatment and distribution channel and categorization of the same at the geography level
  • This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. Compounded annual growth rate is calculated for the respective segments from 2020 to 2027
  • The study includes the profiles of major market players with a significant global and regional presence along with top company positioning

Significant customers?

  • This study is suitable for industry participants and stakeholders in the pharmaceutical companies engaged in the manufacturing and marketing of betahistine for the treatment of Meniere’s disease and vertigo throughout the globe
  • The report will benefit researchers engaged in the orphan drug development of betahistine for the treatment of PWS-linked obesity
  • Managers with financial institutions looking to publish recent and forecasted statistics pertaining to betahistine market
  • Financial institutions venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Ménière’s disease is reigning the treatment segment for the betahistine market. According to the latest research findings provided by the Hearing Health Foundation (HHF), the incidence rate of Ménière’s disease is 12 per 1000 people throughout the globe. It usually affects a single ear initially but in the latter part of life it has been reported to affect both the ears in 15% of the patients. The majority of people suffering with Ménière’s disease are above 40 years, there is no significant difference between the number of men and women population affected. Benign paroxysmal positional vertigo is estimated to register rampant market growth during the forecast period on account of rising prevalence in vertigo and dizziness among the adult population. According to research findings provided by the Oxford University Press vertigo affects about 1 in 3 adults every year.

Hospital pharmacy is dominating the distribution channel segment for the betahistine market. Betahistine being an H1 agonist and H3 antagonist is associated with several drug-related side effects, hence it is necessary for accurate compounding by hospital pharmacists to prevent the occurrence of any unwanted drug-related adverse events. Retail pharmacy is gaining strong grounds in the developing regions owing to the availability of generic versions of betahistine drug formulation at affordable prices.

North America is presently dominating the geography segment for the betahistine market. According to the American Academy of Otolaryngology (AAO), approximately 615,000 people in the United States suffer from Ménière’s disease. The presence of well-developed healthcare infrastructure and domicile of key players such as Auro Pharma, Inc., Sanis Health, Inc., Teva Pharmaceutical Industries Ltd., etc further accentuates the betahistine market growth in the region. Europe is the second-largest regional segment for the betahistine market. As per the latest research citings posted by the World Health Organization (WHO), the annual incidence rate of vertigo is 48.3% in the European Union region. Additionally the strategic collaboration between the academic research institutes and pharmaceutical companies for orphan drug development in the treatment of PWS-linked obesity further propels the market growth in the region. The Asia Pacific is anticipated to register steady market growth during the forecast period on account of the rising prevalence of vertigo migraine across all age groups and the flourishing market for generic drugs in the Asia Pacific region.

Select License Type

$4,600
$6,600
$9,500

Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1560

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.